Loading stock data…
Akebia Therapeutics, Inc. (AKBA)
$0.97-0.01 (-0.87%)
Pre-Market$0.98+0.00 (+0.10%)· Last close Sep 4
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Akebia Therapeutics, Inc. in the Healthcare sector is trading at $0.97 with a market capitalization of $272M. Wall Street consensus targets $3.80 (5 analysts), implying a +289.9% move over the next 12 months. The stock is currently near its 52-week low of $0.81, remaining 24.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +289.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $49.13M↓ | $53.54M↓ | $57.62M↓ | $58.77M↓ | $62.47M |
| Gross Profit | $38.70M↓ | $41.25M↓ | $45.09M↓ | $49.38M↓ | $52.55M |
| Operating Income | -$4.38M↑ | -$4.70M↑ | -$8.55M↓ | $4.45M↓ | $14.09M |
| Net Income | -$8.91M↑ | -$9.05M↑ | -$12.24M↓ | $540,000↑ | $247,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$272.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-118.58%
Volume
Today's trading volume
8.35M
Recent News
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
Akebia Therapeutics Inc (AKBA) reports strong Vafseo growth with over 10,500 patients, while navigating Erixia declines and planning strategic price adjustments for 2027.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics (NASDAQ:AKBA) reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its kidney disease pipeline. Vafseo net product revenue reached $21.3 million in the second quarter of 2026
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 10 that AKBA strengthened the intellectual property protection for its flagship therapy, Vafseo (vadadustat), after receiving a new patent listing in the […]
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic